McKnight M E, Prather K, Koda K, DeBoer K F, Glassy M C
Sci-Clone, Inc., San Diego, CA 92126.
Hum Antibodies Hybridomas. 1991 Oct;2(4):190-3.
The use of the severe combined immunodeficient mouse (SCID), CB-17/Icr//Imd-SCID, was investigated for the production of human hybridoma ascites containing human antibody. Human-human hybridomas, generated from the fusion of lymphocytes isolated from regional draining lymph nodes of cancer patients with the SHFP-1 fusion partner, were injected i.p. at various cell concentrations into pristane-primed SCID mice. Ascites growth was typically observed at 7-14 days postinoculation. No significant differences in ascites yield or production were observed between IgG- and IgM-secreting hybridomas. Yields of immunoreactive human immunoglobulin ranged from approximately 0.5 to 3 mg/ml of harvested ascites. The ease and relatively low cost suggest that the use of SCID mice is preferred over conventional and costly large-scale industrial procedures.
研究了使用严重联合免疫缺陷小鼠（SCID）CB-17/Icr//Imd-SCID来制备含人抗体的人杂交瘤腹水。将从癌症患者区域引流淋巴结分离的淋巴细胞与SHFP-1融合伙伴融合产生的人-人杂交瘤，以不同细胞浓度腹腔注射到经 pristane 预处理的SCID小鼠体内。接种后7 - 14天通常可观察到腹水生长。分泌IgG和IgM的杂交瘤在腹水产量或产生方面未观察到显著差异。收获的腹水中免疫反应性人免疫球蛋白的产量约为0.5至3mg/ml。操作简便且成本相对较低表明，与传统且昂贵的大规模工业程序相比，使用SCID小鼠更为可取。
